mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2

Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019, viral variants with greater transmissibility or immune-evasion properties have arisen, which could jeopardize recently deployed vaccine- and antibody-based countermeasures. Here, we evaluated in mice and ham...

Full description

Saved in:
Bibliographic Details
Published in:Med 2022-05, Vol.3 (5), p.309-324.e6
Main Authors: Darling, Tamarand L., Ying, Baoling, Whitener, Bradley, VanBlargan, Laura A., Bricker, Traci L., Liang, Chieh-Yu, Joshi, Astha, Bamunuarachchi, Gayan, Seehra, Kuljeet, Schmitz, Aaron J., Halfmann, Peter J., Kawaoka, Yoshihiro, Elbashir, Sayda M., Edwards, Darin K., Thackray, Larissa B., Diamond, Michael S., Boon, Adrianus C.M.
Format: Article
Language:English
Subjects:
2019-nCoV Vaccine mRNA-1273 - immunology
2019-nCoV Vaccine mRNA-1273 - pharmacology
Ad26.COV2.S
Ad26COVS1
Animals
Antibodies, Neutralizing
Clinical and Translational
COVID-19 - immunology
COVID-19 - prevention & control
COVID-19 - virology
COVID-19 Vaccines - immunology
COVID-19 Vaccines - pharmacology
Cricetinae
Humans
Influenza, Human
in vivo vaccine efficacy studies
Mice
mouse
mRNA Vaccines - immunology
mRNA Vaccines - pharmacology
mRNA-1273
SARS-CoV-2
SARS-CoV-2 - genetics
SARS-CoV-2 - immunology
Spike Glycoprotein, Coronavirus - immunology
Syrian hamster
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019, viral variants with greater transmissibility or immune-evasion properties have arisen, which could jeopardize recently deployed vaccine- and antibody-based countermeasures. Here, we evaluated in mice and hamsters the efficacy of a pre-clinical version of the Moderna mRNA vaccine (mRNA-1273) and the Johnson & Johnson recombinant adenoviral-vectored vaccine (Ad26.COV2.S) against the B.1.621 (Mu) variant of SARS-CoV-2, which contains spike mutations T95I, Y144S, Y145N, R346K, E484K, N501Y, D614G, P681H, and D950N. Immunization of 129S2 and K18-human ACE2 transgenic mice with the mRNA-1273 vaccine protected against weight loss, lung infection, and lung pathology after challenge with the B.1.621 or WA1/2020 N501Y/D614G SARS-CoV-2 strain. Similarly, immunization of 129S2 mice and Syrian hamsters with a high dose of Ad26.COV2.S reduced lung infection after B.1.621 virus challenge. Thus, immunity induced by the mRNA-1273 or Ad26.COV2.S vaccine can protect against the B.1.621 variant of SARS-CoV-2 in multiple animal models. This study was supported by the NIH (R01 AI157155 and U01 AI151810), NIAID Centers of Excellence for Influenza Research and Response [CEIRR] contracts 75N93021C00014 and 75N93021C00016, and the Collaborative Influenza Vaccine Innovation Centers [CIVIC] contract 75N93019C00051. It was also supported, in part, by the National Institutes of Allergy and Infectious Diseases Center for Research on Influenza Pathogenesis (HHSN272201400008C) and the Japan Program for Infectious Diseases Research and Infrastructure (JP21wm0125002) from the Japan Agency for Medical Research and Development (AMED). [Display omitted] •Ad26.CoV2.S and mRNA-1273 induce high neutralizing antibody titers in mice•Neutralizing antibody responses after vaccination are lower in Syrian hamsters•Ad26.CoV2.S protects mice and hamsters against the Mu variant of SARS-CoV-2•mRNA-1273 protects mice against the Mu variant of SARS-CoV-2 New variants of SARS-CoV-2 have emerged that are more resistant to neutralizing antibodies. Prior to Omicron, the Mu variant (B.1.621) was one of the more neutralizing-antibody-resistant variants of SARS-CoV-2. Here we evaluated the efficacy of two vaccines for protection against the Mu variant in mice and hamsters. Immunization with the mRNA-1273 or Ad26.COV2.S vaccine induced serum neutralizing antibody responses and protected the animals against disease after chal
ISSN:2666-6340
2666-6359
2666-6340
DOI:10.1016/j.medj.2022.03.009